>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: SYNC +7.3%, (reaffirms Q3 guidance; raises FY14 EBITDA guidance; revises strategic plan)

M&A news: ANGI +20.7% (FT reports co hired bankers to explore alternatives, including sale), AKRX +1.3% (acquires Xopenenx Inhalation Soplutions for approx $45 mln in cash; expects this transaction to add ~$18 million to $20 million in revenues and approximately $0.07 to $0.08 of net income per diluted share in 2015)

Select Ebola related names showing strength after CDC confirmed ebola case diagnosed in the US: TKMR +26.8%, HEB +21.9%, LAKE +12.2%, NNVC +10%, NLNK +9.5%, BCRX +8.4%, SRPT +6.6%, INO +5.1%.

Other news: MTL +16.8% (extending yesterday's gains boosted by positive VTB comments), CGEN +5.1% (discloses new results for novel target candidate for cancer immunotherapy; recent data further support CGEN-15049 immune checkpoint role in inhibiting the immune response to cancer cells), RTRX +3.1% (still checking), APP +2.4% (may keep Dov Charney on Board, according to reports), KERX +1.5% (announces issuance of a new U.S. patent for ferric citrate covering orally administrable forms), VE +1.2% (still checking), WAG +1.2% (Express Scripts collaborates with Walgreens (WAG) to create Medicare Prescription Drug Plan pharmacy network), BBRY +1.2% (still checking), .

Analyst comments: AGN +2.1% (upgraded to Buy at Stifel), DYN +1.9% (upgraded to Buy from Neutral at ISI Group), OWW +1.9% (upgraded to Outperform at Oppenheimer), JNS +1.4% (upgraded to Buy from Hold at Jefferies)

Fwd:>>> Airbus - Stock trading higher today, testing its 200d MA...

stock trading on the 49 level -25 since this morning, could see some sellers as 200d MA appear to be a strong resistance...and market trading lower

From: LAURENT CHEKROUN () At: Oct 1 2014 09:25:22
Subject: Fwd:>>> Airbus - Stock trading higher today, testing its 200d MA...
It will be an interesting day on the name, I will be more cautious arround here as so far we saw few PW in cyclical, Basic mat, trading down...not sure investors have very high expectations for Growth on next few months ...after Being aggressively buyer on the name lower (43/44) I will take profit here...I see limited upside 3/4% and more downisde if heavy downturn on market

(Stifel) Allergan upgraded to Buy at Stifel; tgt $200

Allergan upgraded to Buy at Stifel; tgt $200

Stifel upgrades AGN to Buy from Hold and sets target price at $200. AGN continues to resist overtures from VRX (at $72/share cash, 0.83/1.227 exchange ratio). The total value ranges between $175-180 and $220+, considering the theoretical PF value of the combined AGN-VRX entity. AGN maintains that VRX's offer is "grossly inadequate" and has pursued its own strategy to enhance value by 1) driving business performance, 2) executing a restructuring plan, 3) generating pipeline value, and 4) pursuing capital allocation through B/S leverage (with M&A as the ultimate strategy). They believe that AGN retains several options at its disposal to generate greater shareholder return than the VRX offer. They look for developments prior to the 12/18/14 Special Meeting.

(Stifel) Salix Pharma target raised to $185 at Stifel -- M&A prospects beating o

Salix Pharma target raised to $185 at Stifel -- M&A prospects beating out tax inversion oppty

Stifel raises their SLXP tgt to $185 from $155. There have been several developments since announcement of the proposed Cosmo Tech acquisition, giving them pause regarding consummation of the transaction. First, Treasury proposed new regulations in an effort to discourage tax inversions (retroactive to 9/22/14), of which strengthening the "80/20 rule" could directly impact the SLXP-Cosmo merger. Additionally, since August, the potential for SLXP to be a target itself has significantly increased, with possible bids coming from AGN, ACT or others. Based on these developments, we are removing Cosmo from SLXP model for now. Additionally, though they believe SLXP shares are trading at its fundamental value (~$155) they believe the likelihood of a take-out has increased significantly. Assuming a 70% probability of acquisition at a 30% premium (~$200), we raise our price target to $185.

(BFW) Cairn, Genel, Lundin Wells Should Be in Focus This Month: HSBC

Cairn, Genel, Lundin Wells Should Be in Focus This Month: HSBC
2014-10-01 11:49:22.353 GMT


By Benjamin Dow
Oct. 1 (Bloomberg) -- Investors should focus on high-impact
wells for 3 European E&Ps; North Fan (Senegal) for Cairn; Jacare
(Angola) and Nour (Morocco) for Genel; Alta and Vollgrav South
(Norway) for Lundin, HSBC says in note, saying all have material
impact on valuations.
* Cuts Tullow PT 6.1% to 1,000p, keeps overweight; cuts PT on
Africa Oil 17% to C$8.5, also keeps overweight
* Says East Africa Rift Valley is “feature of the month;”
preferred play on region remains Africa Oil
* Claims “exciting” part of drilling program to come in
other basins, may open up similar resource levels to
South Lokichar, providing “step change” in shareholder
value
* Claims “exciting” part of drilling program to come in
other basins, may open up similar resource levels to
South Lokichar, providing “step change” in shareholder
value</li></ul>
* Says North Fan has potential to add 139p/share to Cairn’s
asset value (unrisked), 21p risked; Aragon prospect success
may add 18p/share (unrisked), 5.4p/share (risked)
* Cairn is worst-performing E&P on Stoxx 600 Oil & Gas
Index YTD, has fallen 36%
* Cairn is worst-performing E&P on Stoxx 600 Oil & Gas
Index YTD, has fallen 36%</li></ul>
* NOTE: See Africa Oil Sept. investor presentation slide 12
for future East Africa onshore drill plans

For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the editor responsible for this story:
Benjamin Dow at +7-495-771-7735 or
bdow2@bloomberg.net

>>> US Early premarket gappers

Early premarket gappers
Gapping up: HEB +37.5%, TKMR +28.8%, ANGI +23.9%, LAKE +17.7%, BCRX +14.5%, NLNK +13.7%, NNVC +12%, MTL +8.8%, SYNC +7.3%, SRPT +6.6%, RTRX+3.1%, INO +3%, NBG +1.7%, VE +1.5%, AKRX +1.3%, MBLY +1.1%, SAN +0.9%, DB +0.9%

Gapping down: WPRT -17%, ASEI -6.3%, AAL -3.2%, JBLU -3.2%, UAL -3.2%, DAL -2.8%, SDRL -2.1%, HA -1.9%, LUV -1.9%, EBAY -1.7%, BUD -1.3%, HSBC -1.1%, C -0.9%, CLF -0.7%, BHP -0.7%

>>> Airbus - Stock trading higher today, testing its 200d MA...

It will be an interesting day on the name, I will be more cautious arround here as so far we saw few PW in cyclical, Basic mat, trading down...not sure investors have very high expectations for Growth on next few months ...after Being aggressively buyer on the name lower (43/44) I will take profit here...I see limited upside 3/4% and more downisde if heavy downturn on market

(BofA-ML) BAsic Materials - Most & Least preferred

* Updated Most/Least preferred list
Most preferred
- ArcelorMittal: We are positive on steel margins and view valuation as compelling.
- Lanxess: Good exposure to the most significant self-help plan in European Chems.
- Solvay: Can reach Q3 cons vs. peers whose consensus earnings ests are too high.

Least Preferred
- Glencore: Overvalued, leveraged to weak coal prices.
- K+S: Continue to see material risks in the Ag sector, low dividend yield.
- Akzo Noble: Consensus is complacent around the volume outlook for Deco.

--> Stocks Added and Removed
In this note, we update our Most and Least Preferred Lists (MPL and LPL) of stocks selected from our coverage universe. We also report the performance of the MPL and LPL, and of two strategies based on these lists, the MLP Market Neutral (MN)
and Long/Short (L/S) strategies, since our last publication. The historical performance of the lists and strategies since inception, and the calculation methodologies used, are provided in this report.

--> Performance of MN strategy over previous period: -1.5%
Since our last publication on 1 Sep 2014 until the close on 30 Sep 2014, the MLP MN strategy declined by 1.5%, as the MPL declined by 5.23% and the LPL increased by 3.73%. Over the same period, the STXE 600 Index increased by 0.17% while the S&P EU350 Mats E Index declined by 4.24%.

--> Performance of MN strategy over past 12 months / since inception: +6.68% / +110.28%
Over the 12-month period from 30 Sep 2013 to 30 Sep 2014, the cumulative performance of the MLP MN strategy was +6.68%, as the MPL increased by 9.33% and the LPL declined by 1.47%. Over the same period, the STXE 600 Index increased by 14.16%, while the S&P EU350 Mats E Index increased by 5.26%. Since inception on 14 Mar 2008 to 30 Sep 2014, the cumulative performance of the MLP MN strategy was +110.28%, as the MPL increased by 74.33% and the LPL increased by 21.18%. Over the same period, the STXE 600 Index increased by 44.41%, while the S&P EU350 Mats E Index increased by 6.12%.